Commentary|Videos|April 3, 2025
Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer
Fact checked by: Chris Ryan
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.
Advertisement
Episodes in this series
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
4
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
5